Abstract:Unpleasant side effects of standard inflammatory drugs urges search for novel therapeutic candidates. This study aims in identifying novel anti-inflammatory NF-κB inhibitor by high-throughput computational and in-vitro pre-clinical approaches. Lead candidate selection was conducted by the use of computational docking molecular-dynamic simulations. The RBL-2H3 cell line, derived from rat basophils, was used to evaluate the release of cytokines and degranulation. The study focused on the study of neutrophil elastase and its role in cellular motility. Flow cytometry was utilized to evaluate the activation of basophils and the expression of critical signaling proteins. High throughput screening identified CSB-0914 to stably bind NF-κB-p50 subunit. Dose based loss in T NF-α and IL-2 release were observed in RBL-2H3 cells in addition to degranulation inhibition by CSB-0914. The compound demonstrated significant efficacy in reducing basophil activation assay induced by FcεRI receptors, with an IC50 value of 98.41 nM.. A dose dependent decrease in neutrophil migration and elastase were observed when treated with CSB- 0914. The compound was effective in decreasing. Upon stimulation, RBL-2H3 cells exhibited phosphorylation of NF-κB p-65 as well as upregulation of the Nrf2 and HO-1 signaling pathways. Collectively, our study has successfully identified a novel inhibitor called CSB-0914 that effectively regulates inflammatory responses. These reactions are primarily mediated by the interplay between NF-κB, Nrf2, and HO-1. The findings of this study provide support for the need to conduct more research on CSB-0914 with the aim of its development as a pharmaceutical agent for anti-inflammatory purposes.Communicated by Ramaswamy H. Sarma.

Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB

Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use.

A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks

High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk

Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform

A Genome-Wide CRISPR Screen Supported by Human Genetics Identifies Thetnrc18gene Locus As a Novel Regulator of Inflammatory Signaling

Inflammation Conditional Genome Editing Mediated by the CRISPR-Cas9 System

Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease

Screening NLRP3 drug candidates in clinical development: lessons from existing and emerging technologies

Validation of a CRISPR/cas9-based technology platform for examining specific immune gene functions in an experimental murine model of IBD

Whole-genome CRISPR screen identifies RAVER1 as a key regulator of RIPK1-mediated inflammatory cell death, PANoptosis

Identification of novel inhibitors targeting TIRAP interactions with BTK and PKCδ in inflammation through an in silico approach

A High-Throughput Chemical Screen Identifies Novel Inhibitors and Enhancers of Anti-Inflammatory Functions of the Glucocorticoid Receptor

Targeting T cell plasticity in kidney and gut inflammation by pooled single-cell CRISPR screening

Selective Regulation of a Defined Subset of Inflammatory and Immunoregulatory Genes by an NF-κB p50-IκBζ Pathway

CRISPR/Cas9-targeting of CD40 in Hematopoietic Stem Cells Limits Immune Activation Mediated by Anti-Cd40

Identification and Optimization of Novel Small-Molecule Cas9 Inhibitors by Cell-Based High-Throughput Screening.

S1423 RIPK2 Scaffolding Inhibitors are a Novel Approach to Block RIPK2 Signaling, a Hallmark of Inflammatory Bowel Disease

The "sneaking-ligand" approach: cell-type specific inhibition of the classical NF-κB pathway

Single-Cell Transcriptomic and Targeted Genomic Profiling Adjusted for Inflammation and Therapy Bias Reveal CRTAM and PLCB1 as Novel Hub Genes for Anti-Tumor Necrosis Factor Alpha Therapy Response in Crohn's Disease